MEDIFAST INC Q3 FY2026 earnings call

Strategic Shift to Metabolic Health:

• Launched 'Trilogy,' a new brand and three-phase metabolic health system (Reset, Refine, Renew) focused on preserving lean mass and improving metabolic flexibility rather than just weight loss.
• Introduced MetaVantage technology platform with RESET fuelings, which clinical studies show reduced visceral fat by 14% while retaining 98% of lean mass over 16 weeks.
• Emphasized that quality of weight loss matters more than quantity, differentiating Medifast from GLP-1 competitors who may cause lean muscle loss.

Coach Network & Productivity:

• Active earning coaches declined to ~10,200 from 19,500 in Q3 2025 due to GLP-1 market impact and strategic focus on higher-quality leaders.
• Coach productivity improved for the fourth consecutive quarter, reaching 54% in Q3 (up 8% sequentially).
• Average revenue per active earning coach increased 54.1% YoY to $7,064.
• Simplified compensation plan to reward Executive Director rank holders and streamline advancement.

Operational Efficiency & Technology:

• Executed 'Project Catalyst' restructuring, including facility closures and software sunsetting, resulting in $13.8 million in SG&A charges.
• Implemented 'Trilogy Business Blueprint' unified training system and 'Coach Hub' to standardize skills and reduce administrative burden.
• Integrating AI across business operations to accelerate product development and coach tools, aiming for long-term operating leverage.

Financial Position:

• Ended quarter with $173 million in cash and investments and zero debt.
• Enterprise value remains below cash and investment holdings.

Coach Engagement:

• High engagement and energy levels observed post-launch; 95% of active earning coaches offered new Trilogy products by September.
• Strong belief and capital investment from new generation of coach leaders in the company's mission.

Total Revenue: $72 million (down 19.4% year-over-year). Gross Profit: $50 million (down 19.5% YoY) with a gross margin of 69.5%. SG&A Expense: $69.4 million (up 4.8% YoY), significantly impacted by restructuring charges. Net Loss: $17.5 million ($0.0157 per diluted share). Non-GAAP Adjusted Net Loss: $2.1 million ($0.019 per diluted share). The company does not break down revenue by specific product segment in the transcript, noting instead that total revenue is driven by active earning coach volume and productivity.

• Q4 2026 Revenue: Expected range of $55 million to $75 million.
• Q4 2026 EPS: Expected range of $0.00 to $0.25.
• Full Year 2026 Revenue: Expected range of $280 million to $300 million.
• Full Year 2026 GAAP Loss Per Share: Expected range of $1.80 to $2.05.
• Full Year 2026 Non-GAAP Loss Per Share: Expected range of $0.45 to $0.70.
• Q4 2026 Adjusted EBITDA (excluding interest income): Expected range of $2 million to $6 million.
• Full Year 2026 Adjusted EBITDA (excluding interest income): Expected range of $10 million to $14 million.
• Management anticipates continued decline in active earning coach count through year-end but expects productivity growth to continue.

• Declining Coach Count: The number of active earning coaches has dropped significantly (~10,200 vs 19,500 YoY) and is expected to remain lower in the near term.
• GLP-1 Competition: Rapid adoption of GLP-1 medications is impacting the traditional weight loss category, contributing to revenue decline.
• Execution Risk: Success depends on the effective rollout of the Trilogy brand, compensation plan, and training systems to drive coach growth and retention.
• Restructuring Impact: Project Catalyst charges temporarily inflated SG&A and widened operational losses.
• Market Education: Despite high concern about metabolic health, 80% of US adults have limited understanding of what it means, posing an educational challenge.

Q: How are coaches responding to the rebranding and product changes amidst declining headcount? / A: Nick Johnson reported high engagement and energy levels since the Trilogy launch. The simplified compensation plan anchors rewards on creating healthy Executive Directors (high producers), expecting productivity to rise even as coach quantity falls. Coaches are embracing the new training blueprint and hub, focusing on the metabolic health opportunity rather than just weight loss numbers.

Q: How does the field handle competition from GLP-1s and online weight loss platforms? / A: Johnson noted that GLP-1s are ubiquitous and coaches frequently discuss them with clients. However, the conversation is shifting from quantity of weight lost to quality—specifically preserving lean mass and building muscle, which GLP-1s alone often fail to sustain. Coaches view GLP-1s as a catalyst for starting a health journey but emphasize that a support system is needed for long-term transformation.

Q: Is there data comparing spending for customers on GLP-1s versus those exclusively using Medifast? / A: CFO Jim Maloney stated that while anecdotal surveys indicate some clients use GLP-1s, the company does not centrally track individual customer medication status or order-specific data. Therefore, precise comparative spending metrics between GLP-1 users and exclusive program users are not available or shared.

Q: What other efficiencies can be extracted from SG&A beyond coach compensation adjustments? / A: Maloney explained that Project Catalyst aimed to remove costs that do not impact growth. Looking ahead, the company is leveraging AI and process improvements to achieve further operating leverage. They believe that as they return to growth, they will not need to add back certain fixed costs previously cut, leading to improved operating income in future quarters.